Novelion’s Myalepta gets European approval to treat generalized and partial lipodystrophy

This article was originally published here

Myalepta has been approved as an adjunct to diet, as a replacement therapy to treat the complications of leptin deficiency in lipodystrophy (LD) patients with confirmed congenital generalized

The post Novelion’s Myalepta gets European approval to treat generalized and partial lipodystrophy appeared first on Pharma Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply